At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
An article from
Dive Brief
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
Published Aug. 19, 2026
Cancer vaccines being developed by Moderna, BioNTech and Gritstone are meant to train the immune system to target proteins unique to a person's tumor.
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring | Fortune
Moderna, Merck breakthrough could usher in a wave of cancer vaccines
‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say
Merck, Moderna say melanoma vaccine meets goals in large trial | CBC News
Moderna shares double after experimental mRNA cancer treatment passes key test
New Cancer Treatment Hope After mRNA Vaccine Success
First personalized mRNA cancer vaccine succeeds in Phase 3 trial
Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial
